[
  {
    "ts": null,
    "headline": "Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine",
    "summary": "Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.",
    "url": "https://finnhub.io/api/news?id=cbbf2320ee5c9baf20089e6ab46b37affc06a54f1a3ee03d7d693d3897db75be",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738396800,
      "headline": "Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine",
      "id": 132510138,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2186971023/image_2186971023.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.",
      "url": "https://finnhub.io/api/news?id=cbbf2320ee5c9baf20089e6ab46b37affc06a54f1a3ee03d7d693d3897db75be"
    }
  }
]